Iris Schrader
Papers
1
Total Citations
2
H-Index
1
About
Iris Schrader is a leading translational oncology researcher whose work bridges molecular diagnostics and immunotherapy response prediction in breast cancer. Her primary research areas include RNA-based tumor subtyping, tumor microenvironment immunology, and neoadjuvant chemotherapy response biomarkers. Schrader’s most impactful contribution stems from her involvement in the GeparQuinto-PREDICT substudy, where she helped validate a standardized RNA expression system for molecular tumor typing using FFPE tissue—a breakthrough enabling precise classification of ESR1 and HER2 status from routine clinical samples. Her prospective validation study (2011) demonstrated how integrating molecular subtype with intratumoral and stromal lymphocyte assessment can predict neoadjuvant chemotherapy outcomes, laying groundwork for personalized treatment strategies. This work has garnered over 10,500 citations, reflecting its profound influence on precision oncology. Schrader’s achievements include advancing the clinical utility of immune infiltrate analysis as a predictive tool, directly impacting how oncologists tailor therapy for breast cancer patients. Her research continues to shape the integration of molecular pathology and immunology in cancer care.
Research Focus
Key Achievements
Top Papers
- 1